1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends

Global Pulmonary Arterial Hypertension (PAH) Market: Trends & Opportunities (2015-2019)

  • July 2015
  • 70 pages
  • Daedal Research
Report ID: 3170282

Summary

Table of Contents

Search Inside

Scope of the Report

The report titled “Global PAH Market: Trends and Opportunities (2015-2019)”, analyzes the potential opportunities and significant trends in the global Pulmonary Arterial Hypertension (PAH) market. The market size and forecast in value terms for global PAH market has been provided for the period 2010 to 2019, considering 2014 as the base year. The report also provides the compounded annual growth rate (% CAGR) for the forecast period 2015 to 2019. Over the next five years, Global PAH market revenue is forecasted to remain stable due to patent expiries and launch of new drugs.

The report provides detailed analysis of the global PAH market sizing and growth by type for the period 2010-2014. The market is further segment by drug mechanism and different dosage forms. The analysis of PAH individual drugs sales are also provided in the report.

The report profiles key market players such as Actelion Ltd., United Therapeutics Ltd. and SteadyMed Ltd. on the basis of attributes such as company overview, recent developments, strategies adopted by the market leaders to ensure growth, sustainability, financial overview and recent developments.

Company Coverage
- Actelion Limited
- United Therapeutics Limited
- SteadyMed Limited

PAH Drug Mechanism

- Endothelin Receptor Antagonists (ERA)
- PDE 5 Inhibitors
- Prostacyclins
- sGC Stimulator

Executive Summary

Pulmonary Arterial Hypertension (PAH) is a disease in which high blood pressure occurs in the right ventricle of the heart and the pulmonary arteries that supply blood to the lungs. The increase in pressure is caused by constriction and narrowing of the small pulmonary arteries. In 2005, standard of care was characterized by intravenous treatment aimed at reducing symptoms, not addressing root cause. Now, new treatments are available that go beyond symptom management to treat the underlying cause of PAH. With advancement in the standard of care, patients are able to maintain active lifestyles with a reduced risk of serious heart events associated with PAH.

In 2001, the US Food and Drug Administration (FDA) approved Tracleer as the treatment for patients with PAH. Actelion develop the Tracleer and the sales of Tracleer grew rapidly due to a high patient switch over from off-label drugs to Tracleer. Tracleer, the major revenue generating drug of the PAH market is expected to go off patent by 2015.

Despite an increase in per-member-per-year spend from 2013 to 2014; trend for medications used to treat pulmonary hypertension is expected to be sluggish again in 2015, chiefly because of the market saturation of generic sildenafil. The global PAH market is expected to achieve highest sales till now in the year 2017 due to imminent release of the PAH drug called Uptravi (Selexipag) in 2016, which is anticipated to potentially drive the growth of the total market till 2019. Popularity of combinational therapies is also likely to drive the market in the aforementioned period.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Ahmad helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Axial spondyloarthritis (axSpA) Market and Forecast Analyst to 2024

  • $ 22000
  • Industry report
  • April 2017
  • by Datamonitor Healthcare

Introduction Axial spondyloarthritis (axSpA) is a chronic, systemic, inflammatory rheumatic disease that predominantly affects the spine and sacroiliac (SI) joints, leading to chronic back pain. The chronic ...

OpportunityAnalyzer: Cystic Fibrosis - Opportunity Analysis and Forecasts to 2025

  • $ 10995
  • Industry report
  • April 2017
  • by GlobalData

OpportunityAnalyzer: Cystic Fibrosis - Opportunity Analysis and Forecasts to 2025 Summary Cystic fibrosis (CF), which has been given a the diagnostic code E84 from The International Classification of Diseases, ...

OpportunityAnalyzer: Ovarian Cancer - Opportunity Analysis and Forecasts to 2025

  • $ 10995
  • Industry report
  • May 2017
  • by GlobalData

OpportunityAnalyzer: Ovarian Cancer - Opportunity Analysis and Forecasts to 2025 Summary Ovarian cancer is the fifth most common malignancy in women and is the leading cause of death among gynecological ...

Nash: Kol Insight [2017]

June 2017 $ 9015

Car-t Disease Outlook [2017]

June 2017 $ 8355

Download Unlimited Documents from Trusted Public Sources

Dysfunction Drug Market and Blood Disease Statistics in the UK

  • July 2017
    7 pages
  • Dysfunction Dru...  

    Blood Disease  

  • United Kingdom  

View report >

Therapy and Lipid Modifying Drug Market in the US - Forecast

  • July 2017
    2 pages
  • Therapy  

    Lipid Modifying...  

    Cardiovascular ...  

  • United States  

View report >

Vaccine Market in India - Forecast

  • July 2017
    3 pages
  • Vaccine  

    Infectious Dise...  

  • India  

    Asia  

View report >

Diabetes Statistics

3 days ago

Therapy Market

3 days ago

Related Market Segments :

Therapy
Respiratory Treatment

ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.